BANNOCKBURN, Ill.--(BUSINESS WIRE)--Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today reported strong first quarter 2016 financial results.
“Baxalta’s strong financial performance continues to highlight the attractive growth prospects that exist across the portfolio,” said Ludwig Hantson, chief executive officer and president, Baxalta. “As we embark on the next phase of our journey, the outstanding contributions of our team will result in enhanced access to differentiated therapies that improve patient care and promising new treatments that address unmet medical needs.”
“Baxalta’s strong financial performance continues to highlight the attractive growth prospects that exist across the portfolio,” said Ludwig Hantson, chief executive officer and president, Baxalta. “As we embark on the next phase of our journey, the outstanding contributions of our team will result in enhanced access to differentiated therapies that improve patient care and promising new treatments that address unmet medical needs.”
